LFMD Form 4: Chief Acquisition Officer Receives 100k Shares via Vesting

Rhea-AI Filing Summary

LifeMD insider stock grant vested: Nicholas P. Alvarez, Chief Acquisition Officer of LifeMD, acquired 100,000 common shares on 08/22/2025 as a result of a performance stock grant that vested. The shares were issued at a $0 price, reflecting a vesting award rather than a purchased transaction. Following this vesting, Alvarez beneficially owns 680,000 common shares in total, held directly. The Form 4 was signed on 08/26/2025.

Positive

• 100,000 performance shares vested, converting to common stock at no cash cost to the reporting person
• Increased direct ownership to 680,000 common shares, strengthening insider alignment with shareholders
• Transaction is non-sale compensation, indicating retention or performance-based payoff rather than insider liquidation

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider vesting increased direct ownership by 100,000 shares, a routine compensation event with limited immediate market impact.

The Form 4 discloses a vested performance stock award converting to 100,000 common shares at no cash consideration, raising the reporting person's direct stake to 680,000 shares. This is a non-cash compensation event and should be interpreted as management remuneration rather than an open-market purchase or sale. The transaction gives transparency on insider alignment with shareholders but, standing alone, provides no information on company performance or future expectations. The lack of other transactions or dispositions suggests no immediate insider selling pressure from this reporting person.

Corporate Governance Expert

TL;DR: Vesting of performance shares is a common governance practice to align executives with shareholders; this filing documents that routine outcome.

The filing indicates fulfillment of a performance-based award rather than discretionary cash compensation. Such vesting signals that predetermined performance or service conditions were met, though the Form 4 does not disclose the underlying performance metrics or grant date. From a governance perspective, the conversion of equity awards into common shares strengthens the executive's direct equity stake and aligns incentives long-term. No departures, option exercises, or sales were reported for this reporting person in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alvarez Nicholas P

(Last) (First) (Middle)

C/O LIFEMD, INC.

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Acquisition Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/22/2025		A		100,000	A	$0(1)	680,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of performance stock which vested on August 22, 2025

	/s/ Nicholas P Alvarez	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nicholas P. Alvarez report on the Form 4 for LifeMD (LFMD)?

He reported the vesting of a performance stock award that resulted in the acquisition of 100,000 common shares on 08/22/2025, increasing his direct holdings to 680,000 shares.

Was cash exchanged for the shares reported in the Form 4?

No. The shares were reported at a $0 price, indicating they resulted from a vested performance grant rather than a purchase.

What is the reporting person's role at LifeMD in this filing?

The reporting person, Nicholas P. Alvarez, is listed as Chief Acquisition Officer and an officer of the company.

When was the Form 4 signed and filed?

The signature on the Form 4 is dated 08/26/2025, and the underlying transaction date is 08/22/2025.

Does the Form 4 disclose any sales or dispositions by the reporting person?

No. The Form 4 only reports an acquisition from vested performance stock; there are no reported dispositions in this filing.